Colon cancer screening: Where have we come from and where do we go?

被引:13
|
作者
Chorost, MI
Datta, R
Santiago, RC
Lee, B
Bollman, J
Leitman, IM
Ghosh, BC
机构
[1] Suny Downstate Med Ctr, Brooklyn, NY 11209 USA
[2] New York Harbor Healthcare Syst, Dept Surg, Brooklyn, NY 11209 USA
[3] S Nassau Communities Hosp, Dept Surg, New York, NY USA
[4] Lenox Hill Hosp, Dept Surg, New York, NY 10021 USA
关键词
D O I
10.1002/jso.20008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Many important questions regarding CRC screening still remain. Polypectomy interrupts the adenoma-carcinoma sequence, thereby reducing the formation of cancers. The major limiting factor continues to be compliance for the screening modalities. A nationwide goal has been set by the American Cancer Society to achieve a compliance of 75% in age 50 and older. The current rates are significantly lower and a host of factors are responsible for this issue. These include physician attitudes and beliefs, familiarity with guidelines, patient preferences, and lack of reminder system [35]. There are also a multitude of healthcare system factors, such as insurance status, type of plan, frequency of preventive health visits, and provider recommendations, that lead to underscreening of the population [36,37]. At this stage, we may have effective screening tools for CRC, but there remains a major problem of compliance. Further research is needed to define the optimal methods to improve patient compliance as well as investigating the optimal screening intervals. Additionally, we must identify the most effective strategies to raise public and patient awareness of the magnitude of CRC, its natural history, the importance of familial risk factors, and the available interventions for screening, diagnosis, and treatment. Finally, we must develop useful screening interventions that utilize molecular information in the biology of CRC.
引用
收藏
页码:7 / 13
页数:7
相关论文
共 50 条
  • [1] Antibiotic Discovery: Where Have We Come from, Where Do We Go?
    da Cunha, Bernardo Ribeiro
    Fonseca, Luis P.
    Calado, Cecilia R. C.
    ANTIBIOTICS-BASEL, 2019, 8 (02):
  • [2] Where do we come from, where do we go from here?
    Ammann, K
    Ammann, BP
    METHODS FOR RISK ASSESSMENT OF TRANSGENIC PLANTS, VOL III: ECOLOGICAL RISKS AND PROSPECTS OF TRANSGENIC PLANTS, WHERE DO WE GO FROM HERE? A DIALOGUE BETWEEN BIOTECH INDUSTRY AND SCIENCE, 1999, : 199 - 203
  • [3] Nanoparticles in the environment: where do we come from, where do we go to?
    Mirco Bundschuh
    Juliane Filser
    Simon Lüderwald
    Moira S. McKee
    George Metreveli
    Gabriele E. Schaumann
    Ralf Schulz
    Stephan Wagner
    Environmental Sciences Europe, 2018, 30
  • [4] Elemental speciation: Where do we come from? where do we go?
    Adams, F.C. (freddy.adams@ua.ac.be), 1600, Royal Society of Chemistry (19):
  • [5] Nanoparticles in the environment: where do we come from, where do we go to?
    Bundschuh, Mirco
    Filser, Juliane
    Luderwald, Simon
    Mckee, Moira S.
    Metreveli, George
    Schaumann, Gabriele E.
    Schulz, Ralf
    Wagner, Stephan
    ENVIRONMENTAL SCIENCES EUROPE, 2018, 30
  • [6] Elemental speciation: where do we come from? where do we go?
    Adams, FC
    JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY, 2004, 19 (09) : 1090 - 1097
  • [7] Therapeutic Hypothermia for Brain Ischemia Where Have We Come and Where Do We Go?
    Yenari, Midori A.
    Hemmen, Thomas M.
    STROKE, 2010, 41 (10) : S72 - S74
  • [8] Prostate cancer screening and treatment: where have we come from and where are we going?
    Albertsen, Peter C.
    BJU INTERNATIONAL, 2020, 126 (02) : 218 - 224
  • [9] Tourism, hospitality, and DEA: Where do we come from and where do we go?
    Nurmatov, Ruslan
    Fernandez Lopez, Xose Luis
    Coto Millan, Pedro Pablo
    INTERNATIONAL JOURNAL OF HOSPITALITY MANAGEMENT, 2021, 95
  • [10] Investigation of Brain Function - Where Do We Come from and Where Do We Go?
    Logothetis, Niko K.
    NEUROPSYCHOBIOLOGY, 2018, 77 (03) : 120 - 120